Precision Medicine

Patient-derived xenograft models enable researchers to explore novel therapies and diagnostic tools within the context of specific mutational signatures, treatment histories, and more

By using 3D mini tumor models that closely resemble a patient's tumor, treatments could be tailored more effectively, paving the way for more personalized cancer treatments

Discover how ultrapure water enhances sensitivity, traceability, and reliability in LC-MS for clinical laboratories

New CLIA-certified lab ensures seamless transition from early assay development and testing to full companion diagnostics commercialization

Top experts publish the first standardized guidelines for reporting precision medicine research

An analytical tool called EV fingerprinting could soon replace traditional invasive biopsies for certain diseases

Learn about the role of automation in optimizing FFPE nucleic acid extraction, improving workflow efficiency and reliability

Improve nucleic acid yield and reliability with automation-friendly genomic profiling 

The new platform will help researchers better understand cell-to-cell interactions in tumor microenvironments, benefitting future development of targeted cancer therapies

​​​​​​New research highlights the feasibility of testing for lingering cancer cells for patients in remission from acute myeloid leukemia

Integrating epigenetic insights into cancer research could help deliver personalized, high-quality, and cost-effective patient care

When combined with CA 19-9, the novel biopsy accurately detected 97 percent of stage 1–2 pancreatic cancers

Increasing Phase 2 clinical trial cancellations can have a long-drawn and multifold impact on clinical research

The Plasma Detect™ is the first clinically validated, whole-genome sequencing MRD solution for early-stage colon cancer

A blood test will be better than nothing, but may lead to more CRC cases and deaths than established screening tests

Automation, AI, and digital health technologies can help make clinical trials more efficient, inclusive, and impactful

Treatment for giant axonal neuropathy was well tolerated and slowed loss of motor function

Bulk-sequencing specimen remnants helps advance the development of next-gen diagnostics and personalized treatments

Liquid biopsy helps screen for ctDNA, which is linked to how patients respond to immuno- and chemo-therapy ​

icTCR helps identify suitable T cells from patient samples in under a few days, not months